Testing the safety of agenT-797 cells after a stem cell transplant for blood cancers
Tests whether agenT-797 is safe for adults after a donor stem cell transplant.
Plain-language title generated from the registry record
Registry title: Allogeneic iNKT Cell Therapy (agenT-797) After SCT
Key facts
- Where
- Madison, United StatesSee the site
- Phase
- Phase 1
Where in United States
- University of Wisconsin - MadisonMadison, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Wisconsin, Madison
- Trial code
- NCT07758218
- Record updated
- 29 October 2026
- Original description
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are:Read full original descriptionShow less
UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are:
* Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797?
Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Inclusion: Age ≥18 years at the time of consent; Adult patients anticipated to get an allogeneic hematopoietic cell transplantation (allo-SCT); All donor types are accepted (MMUD [mismatched unrelated donor], MUD [matched unrelated donor], MSD [matched sibling donor], haploidentical); All conditioning regimens will be accepted (MAC [myeloablative conditioning], RIC [reduced-intensity conditioning], NMAC [non-myeloablative conditioning]); Karnofsky Performance Scale (KPS) > 70; Eligible Diagnoses:; Acute myeloid leukemia (AML) with intermediate/high-risk features or relapsed disease; Chronic myeloid leukemia (CML) in accelerated or blast phases; Myelodysplastic syndrome (MDS) with intermediate/high-risk features; Acute lymphoblastic leukemia (ALL) with high-risk features or relapsed disease; or any patients undergoing allogeneic stem cell transplant (allo-SCT) as standard of care could be eligible.
Exclusion: Excluded Diagnoses: Primary Myelofibrosis in the dose escalation phase and could be included in the dose-expansion phase.